References
- Falconi A, Lopes G, Parker JL. Clinical trial risk reduction in non-small cell lung cancer though the use of biomarkers and receptor-targeted therapies. J Clin Oncol. 2013;31(15_suppl):8040.
- Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014 Jun;13(6):419–431.
- Jørgensen JT, Winther H, Askaa J, et al. A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer. Front Oncol. 2021 Jul 23;11:676939.
- Loree JM, Kopetz S, Raghav KP. Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol. 2017 Feb;8(1):199–212.
- Hochmair MJ, Buder A, Schwab S, et al. Liquid-Biopsy-Based Identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib. Target Oncol. 2019 Feb;14(1):75–83.
- Biswas D, Ganeshalingam J, Wan JCM. The future of liquid biopsy. Lancet Oncol. 2020 Dec;21(12):e550.
- Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced Non-Small Cell Lung Cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018 Sep;13(9):1248–1268.
- Adashek JJ, Subbiah V, Kurzrock R. From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm. Trends Cancer. 2021 Jan;7(1):15–28.
- Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). [cited 2022 Mar 30].https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
- Luskin MR, Murakami MA, Manalis SR, et al. Targeting minimal residual disease: a path to cure? Nat Rev Cancer. 2018 Apr;18(4):255–263.
- Hartl D, De Luca V, Kostikova A, et al. Translational precision medicine: an industry perspective. J Transl Med. 2021 Jun 5;19(1):245.